Hybrid business models for ‘Organ-on-a-Chip’ technology: The best of both worlds
Autor: | Regina Luttge, Henk Viëtor, Pim van Dorst, Linda H.M. van de Burgwal, Eric Claassen |
---|---|
Přispěvatelé: | Microsystems, Group Luttge, Athena Institute, Science and Society, APH - Global Health |
Jazyk: | angličtina |
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Pharmacology Computer science Organ-on-a-Chip Customer needs Societal impact of nanotechnology Computer-assisted web interviewing Business model Organ-on-a-chip Preclinical Term (time) Product (business) 03 medical and health sciences 030104 developmental biology Risk analysis (engineering) Pharmacology (medical) Razor Blade Innovation Food Science Hybrid model |
Zdroj: | PharmaNutrition van de Burgwal, L H M, van Dorst, P, Viëtor, H, Luttge, R & Claassen, E 2018, ' Hybrid business models for ‘Organ-on-a-Chip’ technology: The best of both worlds ', PharmaNutrition, vol. 6, no. 2, pp. 55-63 . https://doi.org/10.1016/j.phanu.2018.02.001 PharmaNutrition, 6(2), 55-63. Elsevier PharmaNutrition, 6(2), 55-63. Elsevier BV |
ISSN: | 2213-4344 |
Popis: | Current in vitro and in vivo preclinical models often have limited predictive value for translation to the clinical setting. The emerging ‘Organ-on-a-Chip’ (OOC) technology provides a better resemblance to the human physiology through combining 3D configuration of human-derived cells with microfluidic techniques, potentially improving translation. However, due to the disruptive nature of the OOC technology, it is unclear how to best achieve a product-market fit. Data on currently employed business models was collected by 14 semi-structured interviews with representatives from OOC companies. Customer needs were collected by means of an online questionnaire among 62 (potential) end-users. Both companies and customers preferred the Hybrid business model, in which both products and services were offered. Customized services were only moderately preferred over standard services, limiting the potential for price premiums. Razor blade business models facilitate investments in laboratory equipment while locking in the purchase of disposable OOC devices. Current and future generations of in vitro technologies would benefit from combining the best of product and service business models into the Hybrid business model. Downward price pressures are expected to lead to ever-lower pricing and to facilitate more predictive, high throughput screening with a high societal impact on the longer term. |
Databáze: | OpenAIRE |
Externí odkaz: |